CS32582 / Chipscreen - LARVOL DELTA

Chengdu Microchip Pharmaceuticals CS32582 capsules start Phase Ib/II clinical trials for moderate to severe plaque psoriasis [Google translation] (Sina Corp) - "Data from the Drug Clinical Trial Registration and Information Disclosure Platform show that Chengdu Microchip Pharmaceutical Co., Ltd. has launched a multicenter, randomized, double-blind, placebo-controlled Phase Ib/II clinical trial to evaluate the efficacy and safety of CS32582 capsules in adult patients with moderate to severe plaque psoriasis. The clinical trial registration number is CTR20252671, and the first public information date is July 10, 2025....The primary endpoints of this trial include safety indicators such as adverse events and physical examinations in the first part of the trial, and the proportion of patients whose PASI scores decreased by ≥75% relative to baseline at 12 weeks of treatment in the second part of the trial; secondary endpoints include pharmacokinetic parameters, changes in PASI and other indicators relative to baseline, and the proportion of patients at different stages....Currently, the experiment is in progress (not yet..."

Trial status • Psoriasis

ChipScan Biopharma: CS32582 has completed Phase I clinical trials, and Phase II psoriasis indications are being prepared [Google translation] (163.com) - "According to the financial news on May 7, an investor asked Microchip Biopharma on the interactive platform: Microchip Biopharma's TYK2 inhibitor CS32582 capsule, its clinical trial application for the treatment of psoriasis was approved on October 31, 2023...The company responded: Dear investors, hello. CS32582 has completed Phase I clinical trials, and Phase II psoriasis indications are being prepared."

New P2 trial • Trial completion • Psoriasis

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules (clinicaltrials.gov) - P1 | N=112 | Completed | Sponsor: Chipscreen Biosciences, Ltd. | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Nov 2024

Trial completion • Trial completion date

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: Chipscreen Biosciences, Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules (clinicaltrials.gov) - P1 | N=112 | Not yet recruiting | Sponsor: Chipscreen Biosciences, Ltd.

New P1 trial

Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis (PRNewswire) - "On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd...received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration ('NMPA') through its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd. The notice grants approval for conducting clinical trials of CS32582 capsules in the treatment of psoriasis."

New trial • Immunology • Psoriasis

Microchip: CS32582 Capsule Clinical Trial Application Accepted [Google translation] (Daily Economic News - NBD) - "Microchip...announced on the evening of August 16 that Chengdu Microchip Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the acceptance notice for clinical trials of domestically produced drugs issued by the State Drug Administration. The clinical trial of CS32582 capsules The test application is accepted. The indication of CS32582 capsules is psoriasis."

New trial • Immunology • Psoriasis